|
Latest picks
|
Sector: All 
|
November 26
November 25
|
|
PARD
Biotech Stocks - Beware of The Covered Call Trap
|
|
Years ago when I worked in retail brokerage, I knew a broker at another firm, who specialized in pitching covered call plays. He would explain to clients how with covered calls you take your profits upfront and the premium you just collected gives you a nice cushion to the downside. Say you buy...
|
|
November 24
|
|
ISIS
ISIS - Last Tuesday's Drop Presents a Nice Buy Opportunity
|
|
Shares of Isis Pharmaceuticals ( ISIS ) dropped about 17% on Tuesday, November 17 to close at $11.12, down from a previous close of $13.40. The selloff was a reaction to Isis and partner Genzyme( GENZ )'s presentation for Mipomersen Phase 3 Trials data for treatment of HoFH during at the America...
|
|
November 23
|
|
ABIO
BioMed News Bytes: Transcept, ProUroCare, SciClone, ABIO
|
|
On 11/23/09, Transcept Pharma (NASDAQ: TSPT) announced that it is scheduled to meet with the FDA on 1/20/10 to discuss the Complete Response Letter (CRL) regarding the New Drug Application (NDA) for Intermezzo (zolpidem tartrate sublingual tablet). As previously announced, the CRL, received by TSPT ...
|
|
November 22
|
|
NVO
Diabetes Care: Global Investing Opportunities
|
|
The <font> American Diabetes Association estimates </font> that there are currently 23.6 million diabetics in the U.S. (7.8% of the total population, including 17.9 million diagnosed cases, 5.7 million undiagnosed, and 57 million pre-diabetics. Diabetes results in an estimated $174 billi...
|
|
November 20
|
|
DNDN
BioMed News Bytes: CombinatoRx, Dendreon, Photocure, Pozen
|
|
On 11/2/09, Dendreon (NASDAQ: DNDN) announced that it has completed the submission of its amended Biologics License Application (BLA) for PROVENGE (sipuleucel-T), seeking approval for men with metastatic castrate-resistant prostate cancer (CRPC). The amended BLA includes data from the IMPACT trial, ...
|
|
November 19
|
|
ONCY
Oncolytics Biotech Inc. down to 2,00 $
|
|
http://cxa.marketwatch.com/TSX/en/Market/article.aspx?guid=ht... CALGARY, Nov 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (ONC)(US:ONCY) announced today that it has entered into an underwriting agreement for an offering of 4,250,000 units, ...
|
|
|
|
JNJ
Epinex Diagnostics: A New Paradigm for Diabetic Testing
|
|
Epinex Diagnostics Inc. (click on preceding link for the Company's News Room page) is a private company that is dedicated to the development of innovative point-of-care technologies using rapid diagnostic tests. Epinex has developed a proprietary platform for rapid tests that apply existing i...
|
|
November 17
|
|
CERS
BioMed News Bytes: GeoVax, Cerus, Discovery Labs
|
|
On 11/17/09, GeoVax (OTC: GOVX.OB) announced that the FDA has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug (IND) application for the Company’s therapeutic vaccine as a treatment for individuals already infected with HIV. The meeting will only take ...
|
|
|
|
CVI
Short CVR Energy Inc (CVI)
|
|
Insiders are selling Revenues are down EPS are going down CVI underperform compare with the market last 3m About the ETF Market | ETF Podcast Gold Investment | Gold Coins CVR Energy, Inc., together with its subsidiaries, refines and markets transport...
|
|
|
|
SKS
Saks is not a sucker play ; but it will be- buy now.
|
|
The market : Saks is at $6.60 SG&A (Selling, General & Administrative expenses, a key component of costs) was basically flat compared to last year. Year over year, comparable store sales declined 10.1 percent . My view is this is a great stock to buy, when retail come...
|
|
November 16
|
|
CYTX
BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
|
|
On 11/16/09, Cytori Therapeutics (NASDAQ: CYTX) completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastecto...
|
|
|
|
TBAC
Bullish on TBAC ...
|
|
Tandy Brands Accessories, Inc. (NASDAQ:TBAC) declined 10.97% to $3.41 after the company reported results for the first quarter of fiscal 2010 ended September 30. At the end of the first quarter, Tandy had $1.9 million of cash and borrowings of $16.5 million under its $27.5 million credit facility. In...
|
|
November 15
|
|
OCNF
Ocean Freight dry bulk shipping
|
|
Dry bulk shippers been really hurt as a group. It's a play on recovery in global shipping like Warren B with his railroads. OCNF just reported ok 3Q w/ money after taking loss on selling one ship. Bought bigger one w/ revs already locked in and 2 more ships to be bought soon. ...
|
|
|
|
Get Daily Alerts
in Email/BlackBerry
Get free alerts and recommendations from proven top-performing SocialPicks members
|
Top Rated Stocks
|
Comment
